Interpace Biosciences Files S-1/A Amendment Ahead of IPO
Interpace Biosciences, Inc. (SEC file no. 0001054102), a Nasdaq-listed biotech company (ticker: IDXG), filed an amended Form S-1/A with the SEC on October 1, 2026. The 779 KB filing likely updates financials, risk factors, or underwriting terms as part of its ongoing IPO process.
51CFO view：For listed companies pursuing spin-offs or secondary listings, S-1/A amendments often trigger SEC requests for retrospective financial restatements (e.g., ASC 805, ASC 718). CFOs must have SEC continuous disclosure experience and expertise in biotech-specific accounting — especially ASC 606 revenue recognition and R&D capitalization policies.
Interpace Biosciences, Inc. (SEC file no. 0001054102), a Nasdaq-listed biotech company (ticker: IDXG), filed an amended Form S-1/A with the SEC on October 1, 2026. The 779 KB filing likely updates financials, risk factors, or underwriting terms as part of its ongoing IPO process.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
What to do 18 months before filing
Financial readiness: audit basis, internal control, equity restatement.
Read →